Thirty-eight microorganisms were screened for their ability to produce metabolites of the semisynthetic alkaloid, lergotrile. A total of five microorganisms were found to biotransform lergotrile, and N-desmethyl lergotrile was detected as the principal metabolite with most organisms. Streptomyces platensis (NRRL 2364) appeared to form the metabolite in highest yield, and a preparative-scale conversion was accomplished with a recovered yield of 50%. Structure proof was accomplished with comparative thin-layer chromatography, mixed melting point, mass spectrometry, and remethylation to lergotrile.
Recent interest in lergotrile ( Fig. 1, I ) stems from its putative dopaminergic activity and inhibition of prolactin secretion. Lergotrile has been tested extensively in treatment of Parkinsonism and shown to provide marked reduction in tremors (8) . It has been effective in treating galactorrhea of many etiologies due to its inhibition of prolactin secretion (5) . It may also be useful in treating acromegaly (6) and reversing infertility in women (3) . However, side effects of orthostatic hypotension, mental change, and abnormal liver function have been observed with its use. The hepatotoxicity is particularly disturbing and has disrupted clinical trials (1) . This toxicity may be related to the biotransformation of lergotrile in man and has prompted a study of lergotrile's microbial metabolism. Using the strategy of reference 10, a primary objective is to obtain sizable quantities of metabolites for structural identification and biological testing.
In guinea pigs, lergotrile is converted to desmethyl lergotrile (Fig. 1, II) ; lergotrile is also hydroxylated at position thirteen, and is subject to hydrolysis of its nitrile function (C. J. Parli and B. Schmidt, Fed. Proc. 34:813, 1975 ). The phenolic metabolite 13-hydroxylergotrile has also been found in humans (9) . Initial efforts to describe microbial systems that mimic the mammalian metabolism of lergotrile have led to the discovery that Streptomyces platensis (NRRL 2364) produces the N-demethyl metabolite in high yield. The preparative-scale production of desmethyl lergotrile using S. platensis is the subject of this report.
MATERIALS AND Preparative-scale production of desmethyl lergotrile. S. platensis (maintained on ATCC medium 5 sporulation agar slants) was grown in a manner similar to the procedure described above but with the following exceptions: 6 ml of the stage 1 culture was used to inoculate each of eight stage 2 250-ml Erlenmeyer flasks containing 50 ml of medium. It was necessary to incubate these stage 2 flasks for 72 h rather than 24 h before substrate addition to obtain adequate growth of S. platensis. Lergotrile mesylate (100 mg) in 800 ul of sterile water was distributed evenly among the stage 2 cultures (final concentration, 0.25 mg/ml). After 2 days of incubation, complete conversion of substrate was shown by TLC system iii. The entire fermentation culture was exhaustively extracted by combining 10-ml portions with 10 ml of 0.1 M sodium carbonate/sodium bicarbonate buffer (pH 8.5) and 10 ml of diethyl ether in each of forty, 50-ml screw-capped test tubes (silyated with 2% trimethylsilyl chloride [Pierce] in toluene and dried at 100°C for 1 h). The tubes were rocked on a Lab-Tek Aliquot Mixer (30 oscillations per min) for 30 min. The tubes were centrifuged (1,230 x g) for 2 to 3 min, and the ether layers were drawn off and combined. The ether extract was dried with anhydrous Na2SO4 and evaporated to dryness in vacuo. The residue (84 mg) was redissolved in 5 ml of methanol and applied to two preparative TLC plates (20 by 20 cm, silica gel PF 254 [Merck], 1.0 mm thickness; activated at 100°C for 1.5 h). Development was carried out in chloroform-methanol-acetone-NH40H (28%) (63:7:27:2, vol/vol). The band representing desmethyl lergotrile, located with short-wavelength (254 nm) ultraviolet light, was scraped off, and the metabolite was eluted with acetone. Filtration and evaporation of solvent afforded 36.2 mg of desmethyl lergotrile (pure by TLC) which represents approximately 50% recovery. The product was crystallized from methanol, the mp ofthis material (221 to 224°C) was identical with authentic desmethyl lergotrile, and there was no depression of mp upon admixture. A mass spectrum (ms) of the product was (2) . A 2-mg portion of metabolite desmethyl lergotrile was remethylated to lergotrile by treatment with formaldehyde and sodium borohydride at room temperature (7) , as indicated by TLC in system iii. Since some of the mammalian metabolites of lergotrile are potent dopamine agonists (9), correlating metabolic pathways in microbial and mammalian species offer the potential of largescale production of more clinically suitable derivatives. Since desmethyl lergotrile is a metabolite in microbes and mammals, it appears feasible that other mammalian metabolites might be made available through continued study. The preparation of desmethyl lergotrile from lergotrile as described in this report provides additional evidence for the utility of the "microbial models" approach in drug metabolism studies (10).
